Inovio Pharmaceuticals (NSDQ:INO) has inked an amended collaboration and licensing deal with ApolloBio for its DNA immunotherapy product designed to treat the pre-cancers caused by human papillomavirus. The exclusive partnership is limited to China, Hong Kong, Macao and Taiwan, but it could also include the Republic of Korea over the next three years, Inovio reported. In […]